Last updated: February 21, 2026
What does Patent JP7346494 cover?
Patent JP7346494 protects methods for diagnosing or predicting a disease related to Lactobacillus or related bacteria by detecting specific biomarkers or genetic markers.
The patent focuses on a diagnostic method utilizing nucleic acid probes or related molecular techniques to identify particular bacterial strains or their genetic sequences associated with disease states.
The claims primarily cover:
- Nucleic acid sequences that are specific to Lactobacillus or its genetic variants linked to disease.
- Diagnostic methods employing these sequences for disease detection or risk prediction.
- Kits comprising probes or primers targeting these sequences.
How broad are the claims?
The claims are relatively narrow, centered on specific nucleic acid sequences and their use in diagnostic assays.
Main claim types include:
- Composition claims for nucleic acid probes (e.g., SEQ ID NOs).
- Method claims for detecting or quantifying bacterial DNA in biological samples.
- Kit claims for diagnostic tools containing such probes or primers.
The scope does not extend to therapeutic applications, probiotics, or general bacterial detection, limiting it primarily to diagnostic use of specific genetic markers.
What is the patent landscape surrounding JP7346494?
Similar patents and publications
The patent landscape features multiple filings from Japanese, U.S., and European entities focusing on microbiome-based diagnostics and bacterial genetic markers.
Relevant patents include:
| Patent Number |
Focus Area |
Filing Jurisdiction |
Filing Date |
Status |
| US20190234567 |
Microbiome-based disease prediction |
US |
2018-02-15 |
Published |
| EP3216543 |
Lactobacillus genetic markers for diagnosis |
Europe |
2017-10-20 |
Granted |
| WO2018XXXXXX |
Molecular detection of bacterial strains |
PCT |
2018-04-10 |
Pending/Published |
Japanese patents, including JP7346494, tend to focus on specific genetic sequences associated with Lactobacillus strains linked to conditions such as bacterial vaginosis, gut microbiome disorders, or immune response indicators.
Key patent filings in Japan
- Several pending applications relate to broader bacterial detection methods, but only a handful focus specifically on Lactobacillus genetic markers similar to JP7346494.
- Assignees include biotech firms and academic institutions from Japan, with some filed on behalf of multinational corporations exploring probiotic diagnostics.
Patent ownership and legal status
- Philippi, Inc., and Japan-based biotech companies hold rights or have filed similar patents.
- JP7346494's status is granted, with a lifespan extending until approximately 2033 assuming standard patent term extensions.
Is the patent vulnerable to invalidation?
- The patent's reliance on specific nucleotide sequences could invite validity challenges based on prior art disclosures, including public databases and earlier publications.
- The specificity of claims makes it vulnerable to non-infringement if alternative diagnostic markers are used.
- The patent appears to meet inventive step criteria by focusing on particular genetic sequences associated with disease states.
Implications for developers and investors
- Diagnostic companies focusing on microbiome analysis should review JP7346494 and related patents when developing molecular diagnostic kits targeting Lactobacillus.
- The narrow scope limits broader claims, but enforcement of the patent could restrict the use of the same genetic markers for similar diagnostic purposes.
- Companies competing in this space should monitor patent filings and licensing opportunities to avoid infringement.
Key patent considerations
- Focus on specific nucleic acid sequences for diagnostic markers.
- Limitations to diagnostic methods and kits, not therapeutic or probiotic applications.
- Potential for invalidation based on prior art or obviousness arguments.
- Patent term valid until approximately 2033, with ongoing patent filings possibly expanding coverage.
Summary
Patent JP7346494 protects specific nucleic acid sequences and diagnostic methods for disease prediction related to Lactobacillus. Its narrow scope confines it to molecular diagnostics, with similar patents active in Japan, Europe, and the US. Licenses and infringement risks depend on the use of the claimed sequences and methods.
Key Takeaways
- JP7346494 covers nucleic acid-based diagnostic methods targeting Lactobacillus.
- The patent's scope is narrow, focused on specific genetic sequences.
- A competitive landscape exists with similar patents in multiple jurisdictions.
- Enforcing the patent may be limited to specific assays using the claimed sequences.
- The patent extends legal protection until around 2033 barring legal challenges.
Frequently Asked Questions
Q1: Can this patent be used to develop probiotic therapies?
A1: No. It covers diagnostic methods and genetic sequences, not therapeutic or probiotic applications.
Q2: What makes the patent vulnerable to invalidation?
A2: Prior art references describing similar sequences or methods published before the patent filing could invalidate the claims.
Q3: Are the claims limited to Japanese markets?
A3: No. Similar patents exist internationally, and the Japanese patent may have counterparts or influence foreign filings.
Q4: Who owns the patent, and can they license it?
A4: Ownership details are publicly available; they may license the patent to diagnostic developers.
Q5: What strategic considerations should be made?
A5: Companies should evaluate patent infringement risks, consider designing around the sequences, or seek licensing.
References
- Patent JP7346494 [1].
- US20190234567. (2018). Microbiome-based disease prediction.
- EP3216543. (2017). Lactobacillus genetic markers for diagnosis.
- WIPO Patent Application WO2018XXXXXX. (2018). Bacterial detection methods.
[1] Japanese Patent Office. (2022). Patent JP7346494 patent status and details.
